0001213900-18-006355.txt : 20180515 0001213900-18-006355.hdr.sgml : 20180515 20180515165240 ACCESSION NUMBER: 0001213900-18-006355 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180515 DATE AS OF CHANGE: 20180515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American BriVision (Holding) Corp CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-91436 FILM NUMBER: 18837416 BUSINESS ADDRESS: STREET 1: 11 SAWYERS PEAK DRIVE CITY: GOSHEN STATE: NY ZIP: 10924 BUSINESS PHONE: 845-551-8728 MAIL ADDRESS: STREET 1: 11 SAWYERS PEAK DRIVE CITY: GOSHEN STATE: NY ZIP: 10924 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 FORMER COMPANY: FORMER CONFORMED NAME: Ecology Coatings, Inc. DATE OF NAME CHANGE: 20070711 10-Q 1 f10q0318_americanbrivision.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission file number 333-91436

American BriVision (Holding) Corporation.

(Exact name of Registrant as specified in its charter)

Nevada

26-0014658

State or jurisdiction of

incorporation or organization

IRS Employer

Identification Number

11 Sawyers Peak Drive, Goshen, NY 10924

Tel: 845-291-1291

(Address and telephone number of principal executive offices)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of May 15, 2018, there were 213,926,475 shares of common stock, par value per share $0.001, issued and outstanding.

TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	F-1

Item 1.	Financial Statements (Unaudited)	F-1
	Consolidated Balance Sheets as of March 31, 2018 (Unaudited) and December 31, 2017	F-2
	Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017 (Unaudited)	F-3
	Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017 (Unaudited)	F-4
	Notes to Unaudited Consolidated Financial Statements	F-5 - F-16
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	9
Item 4.	Controls and Procedures	9

PART II	OTHER INFORMATION	10

Item 1.	Legal Proceedings	10
Item 1A.	Risk Factors	10
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	10
Item 3.	Defaults Upon Senior Securities	10
Item 4.	Mine Safety Disclosures	10
Item 5.	Other Information	10
Item 6.	Exhibits	10
Signatures		11

CAUTIONARY NOTE ON FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains “forward-looking statements” which discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “anticipate,” “believe,” “estimate,” “intend,” “could,” “should,” “would,” “may,” “seek,” “plan,” “might,” “will,” “expect,” “predict,” “project,” “forecast,” “potential,” “continue” and negatives thereof or similar expressions. Forward-looking statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future and are not guarantees. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements.

These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Risks Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K and its amendment filed with the Securities and Exchange Commission (the “SEC”); in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Report, and information contained in other reports that we file with the SEC. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.

There are important factors that could cause actual results to vary materially from those described in this report as anticipated, estimated or expected, including, but not limited to: competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins, volatility in the securities market due to the general economic downturn; SEC regulations which affect trading in the securities of “penny stocks,” and other risks and uncertainties. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward- looking statements, even if new information becomes available in the future. Depending on the market for our stock and other conditional tests, a specific safe harbor under the Private Securities Litigation Reform Act of 1995 may be available. Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. Because we may from time to time be considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.

As used in this Report, the terms “we”, “us”, “our”, and “our Company” and “the Company” refer to American Brivision (Holding) Corporation (formerly known as Metu Brands, Inc.) and its subsidiaries, unless otherwise indicated.

PART I- FINANCIAL INFORMATION

Item 1.

Financial Statements.

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

Index to the Financial Statements

		Page

Consolidated Unaudited Balance Sheets at March 31, 2018 and December 31, 2017		F-2

Consolidated Unaudited Statements of Operations for the three months ended March 31, 2018 and 2017		F-3

Consolidated Unaudited Statements of Cash Flows for the three months ended March 31, 2018 and 2017		F-4

Notes to Consolidated Unaudited Financial Statements		F- 5 - F-16

F-1

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2018			December 31, 2017
	(Unaudited)
Assets
Current assets
Cash	$	5,675		$	93,332
Receivable from collaboration partners – related parties		2,550,000			2,550,000
Total Current Assets		2,555,675			2,643,332

Total Assets	$	2,555,675		$	2,643,332

Liabilities and Equity
Accrued expense		202,684			170,927
Due to related parties		4,286,320			4,229,320
Total Liabilities	$	4,489,004		$	4,400,247

Commitments and Contingencies

Stockholders’ deficit
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,926,475 and 213,746,647 at March 31, 2018 and December 31, 2017, respectively		213,927			213,747
Additional paid-in capital		13,891,382			13,805,936
Accumulated deficit		(16,038,638	)		(15,776,598	)
Total stockholders’ deficit		(1,933,329	)		(1,756,915	)
Total Liabilities and Equity	$	2,555,675		$	2,643,332

The accompanying notes are an integral part of these consolidated financial statements.

F-2

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	For The Three Months Ended March 31,
	2018			2017
Revenues	$	-		$	-

Cost of revenues		-			-

Gross profit		-			-

Operating expenses
Selling, general and administrative expenses		175,864			208,315
Research and development expenses		45,055			25,150
Stock based compensation expenses		5,626			3,376

Loss from operations		(226,545	)		(236,841	)

Other income(expenses)
Interest expense		(33,645	)		(19,000	)
Total other expenses		(33,645	)		(19,000	)

Loss from continuing operations before provision income tax		(260,190	)		(255,841	)

Provision income tax		1,850			830

Net Loss and Comprehensive Loss	$	(262,040	)	$	(256,671	)

Net loss per share
Basic and diluted	$	(0.00	)	$	(0.00	)
Weighted average number of common shares outstanding
Basic and diluted		213,754,639			212,056,647

The accompanying notes are an integral part of these consolidated financial statements.

F-3

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For The Three Months Ended March 31,
	2018			2017
Cash flows from operating activities
Net loss from continuing operations	$	(262,040	)	$	(256,671	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		5,626			3,376
Change in operating assets and liabilities:
Increase in accrued expenses and other current liabilities		111,757			41,060
Increase (decrease) in due to related parties		7,000			(650,000	)
Net cash used in operating activities		(137,657	)		(862,235	)

Cash flows from financing activities
Borrowings from related parties		50,000			950,000
Net cash provided by financing activities		50,000			950,000
Effect of exchange rates on cash		-			-
Net increase (decrease) in cash		(87,657	)		87,765

Cash, beginning of period		93,332			18,645

Cash, end of period	$	5,675		$	106,410

Supplemental disclosure of cash flow information

Interest expense paid	$	31,945		$	9,500
Income taxes paid	$	1,850		$	830

Non-cash financing and investing activities

Common shares issued for due to related parties	$	-		$	5,850,000
Common shares issued for employees	$	80,000		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-4

AMERICAN BRIVISION (HOLDING) CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2018

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had no predecessor operations prior to its formation on July 21, 2015.

Reverse Merger

On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).

Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”).

Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision has become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.

Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.

Accounting Treatment of the Reverse Merger

For financial reporting purposes, the Share Exchange represented a “reverse merger” rather than a business combination and BriVision was deemed the accounting acquirer in the transaction. The Share Exchange was being accounted for as a reverse-merger and recapitalization. BriVision was the acquirer for financial reporting purposes and the Company was the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange were those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange included the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

F-5

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated unaudited financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

Fiscal Year

The Company changed its fiscal year from the period beginning on October 1^st and ending on September 30^th to the period beginning on January 1^st and ending on December 31^st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30^th of such year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

Reclassifications

Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.

Forward Stock split

On March 21, 2016, the Board of Directors of the Company approved an amendment to its Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to the Articles of Incorporation.

Fair Value Measurements

The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

F-6

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.

Cash and Cash Equivalents

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2018 and December 31, 2017, the Company’s cash and cash equivalents amounted $5,675 and $93,332, respectively. The Company’s cash deposits are held in financial institutions located in both Taiwan and the United States of America where there are currently regulations mandated on obligatory insurance of bank accounts. The Company believes these financial institutions are of high credit quality.

Concentration of Credit Risk

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.

Receivable from Collaboration Partners

Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

Research and Development Expenses

The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.

Stock-based Compensation

The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2018 and 2017.

The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 718 “Compensation-Stock Compensation” and ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $5,626 and $3,376 for the three months ended March 31, 2018 and 2017, respectively.

Income Taxes

The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.

F-7

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2018 and 2017. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”). In accordance with this guidance, the Company’s financial results reflect provisional amounts for those specific income tax effects of the 2017 Tax Act for which the accounting under ASC Topic 740 is incomplete but a reasonable estimate could be determined. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

For the three months ended March 31, 2018 and 2017, the Company’s income tax expense amounted to $1,850 and $830, respectively.

Loss Per Share of Common Stock

The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.

Commitments and Contingencies

The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017 and ASU No. 2018-01, in January 2018, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of determining the method of adoption and assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.

F-8

In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients and ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting . In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. ASU 2016-10 clarifies the following two aspects of ASU 2014-09: identifying performance obligations and licensing implementation guidance. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. ASU 2016-12 provides clarification to Topic 606 on how to assess collectability, present sales tax, treat noncash consideration, and account for completed and modified contracts at the time of transition. ASU 2016-12 clarifies that an entity retrospectively applying the guidance in Topic 606 is not required to disclose the effect of the accounting change in the period of adoption. Additionally, ASU 2016-20 clarifies certain narrow aspects within Topic 606 including its scope, contract cost accounting, and disclosures. The new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations to customers and significant judgments in measurement and recognition. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the overall impact that ASU 2014-09 and its related amendments will have on the Company’s financial statements.

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”).To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

In February 2018, the FASB issued Accounting Standards Update No. 2018-02 (ASU 2018-02), Income Statement - Reporting Comprehensive Income (Topic 220). The guidance in ASU 2018-02 allows an entity to elect to reclassify the stranded tax effects related to the Tax Cuts and Jobs Act (the Tax Act) of 2017 from accumulated other comprehensive income into retained earnings. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements.

3. GOING CONCERN

The accompanying consolidated unaudited financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $16,038,638 as of March 31 2018 and incurred net loss of $262,040 during the three months ended March 31, 2018. The Company also had a working capital deficiency of $1,933,329 at March 31, 2018. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These unaudited consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management’s plans to obtain such resources for the Company include (1) obtaining capital from the sale of its equity securities (2) short-term and long-term borrowings from banks and third-parties, and (3) short-term borrowings from stockholders or other related party(ies) when needed. However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually to secure other sources of financing and attain profitable operations.

F-9

4. COLLABORATIVE AGREEMENTS

Collaborative agreement with BioLite Inc., a related party

On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the “BioLite Collaborative Agreement”) with BioLite Inc. (the “BioLite”), a related party (See Note 6), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision is obliged to pay up to a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:

	●	upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.

	●	upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.

	●	upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.

	●	upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.

This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.

Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.00 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.

Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of March 31, 2018, the first phase II clinical trial research has not been completed yet.

The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense when incurred.

On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.

F-10

Co-Development agreement with Rgene Corporation, a related party

On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by the controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 6). Pursuant to the Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides the $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.

On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended September 30, 2017, the Company has received $450,000 in cash. As of the date of this report, the Company is still in discussion with Rgene with respect to the schedule of the outstanding balance of $2,550,000.

Collaborative agreement with BioFirst Corporation, a related party

On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7).

Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.

On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 has been fully expensed as research and development expense during the year ended September 30, 2017.

5. ACCRUED EXPENSES

Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of:

	March 31, 2018		December 31, 2017
Accrued consulting fee	$	26,000	$	29,075
Accrued professional service fees		12,961		13,592
Accrued interest expense – related party(Note 6)		19,160		17,460
Accrued payroll		141,500		110,800
Accrued operating expenses		3,063		-
Total	$	202,684	$	170,927

F-11

6. RELATED PARTIES TRANSACTIONS

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsianGene Corporation (the “AsianGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Chairman, interim CFO and former President

Due to related parties

Amount due to related parties consisted of the following as of the periods indicated:

	March 31,		December 31,
	2018		2017
BioLite, Inc.	$	109,220	$	109,220
BioFirst Corporation		3,964,000		3,957,000
AsianGene Corporation		160,000		160,000
YuanGene Corporation		53,000		3,000
Eugene Jiang		100		100
Total	$	4,286,320	$	4,229,320

Related party transactions

(1)	As of March 31, 2018 and December 31, 2017, BioLite has advanced an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

(2)

On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. On February 2, 2018, the Company and BioFirst agreed to extend the maturity date of loan to February 1, 2019 with the same terms of the original loan agreement. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $950,000 and accrued interest is $17,960 and $17,460 (See Note 5). Interest expenses in connection with this loan were $28,500 and $19,000 for the three months ended March 31, 2018 and 2017, respectively.

(3)

On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 4). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst.

(4)	As of March 31, 2018 and December 31, 2017, BioFirst has advanced in an aggregate amount of $14,000 and $7,000 to the Company for working capital purposes, respectively. The advances bear 0% interest rate and are due on demand.

(5)

In September 2017, AsianGene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of March 31, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $160,000. Interest expenses in connection with this loan were $3,945 and $0 for the three months ended March 31, 2018 and 2017, respectively.

(6)	As of March 31, 2018 and December 31, 2017, YuanGene Corporation has advanced an aggregate amount of $3,000 to the Company for working capital purposes. The advances bear 0% interest rate and are due on demand.

(7)

On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 17, 2019. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $50,000 and $0, and accrued interest is $1,200 and $0 (See Note 5), respectively. Interest expenses in connection with this loan were $1,200 and $0 for the three months ended March 31, 2018 and 2017, respectively.

F-12

(8)	As of March 31, 2018 and December 31, 2017, the Chairman of the Company has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

(9)

On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 4). As of March 31, 2018 and December 31, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017.

(10)

During the three months ended March 31, 2017, the Company entered an operating lease agreement with AsianGene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $0 and $15,000 for the three months ended March 31, 2018 and 2017, respectively.

7. EQUITY

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.

On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. As a result, all shares outstanding for all periods have been retroactively restated to reflect Company’s 1 to 3.141 forward stock split.

The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.

On August 26, 2016, the Company issued 1,468,750 common stock shares of the Company, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering was $1.60. The net proceeds to the Company from the Offering were approximately $2,350,000. The proceeds may be used for general corporate purposes.

F-13

Pursuant to the BioLite Collaborative Agreement (See Note 4), BriVision is obliged to pay up to a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.00 per share, for an aggregate number of 2,925,000 shares.

On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. On October 1, 2017, the contract was extended for one year ending at September 30, 2018. On March 28, 2018, the Company issued 4,828 common stock shares of the Company at $1.60 per share in a total of $7,725 to Kameyama in connection with this consulting agreement.

On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) and the Company entered into a one-year service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. On March 28, 2018, the Company issued 50,000 common stock shares of the Company at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.

On January 1, 2017, Kimho Consultants Co., Ltd. (the “Kimho”) and the Company entered into a one-year service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. On March 28, 2018, the Company issued 75,000 common stock shares of the Company at $1.60 per share in a total of $120,000 to Kimho in connection with the Kimho Agreement.

Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.

On March 28, 2018, the Company also issued an aggregate of 50,000 common stock shares of the Company at $1.60 per share for salaries in a total of $80,000 to three officers.

8. INCOME TAX

The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013.

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of March 31, 2018 and December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at March 31, 2018 and December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the three months ended March 31, 2018 and for the year ended December 31, 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.

F-14

Components of income tax (benefits) for the three months ended March 31, 2018 and 2017 are as follows:

	For the Three Months Ended March 31,
	2018						2017
	Federal		State		Total		Federal		State		Total
Current	$	-	$	1,850	$	1,850	$	-	$	830	$	830
Deferred		-		-		-		-		-		-
	$	-	$	1,850	$	1,850	$	-	$	830	$	830

Significant components of the Company’s deferred tax accounts at March 31, 2018 and December 31, 2017:

Deferred Tax Account - noncurrent:	March 31, 2018			December 31, 2017
Tax losses carryforwards	$	647,960		$	594,501
Less: Valuation allowance		(647,960	)		(594,501	)
Total deferred tax account - noncurrent	$	-		$	-

The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:

	For the Three Months Ended March 31,
	2018			2017
Statutory federal tax benefit, net of state tax effects		19	%		31	%
State income taxes		8.84	%		8.84	%
Nondeductible/nontaxable items		(2	)%		(1	)%
Change in valuation allowance		(24.84	)%		(38.84	)%
Effective income tax rate		1	%		-	%

9. LOSS PER SHARE

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31, 2018 and 2017.

	For the Three Months Ended March 31,
	2018			2017

Numerator:
Net loss	$	(262,040	)		(256,671	)

Denominator:
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic		213,754,639			212,056,647
Stock options		-			-
Weighted-average shares outstanding - Diluted		213,754,639			212,056,647

Loss per share
-Basic		(0.00	)		(0.00	)
-Diluted		(0.00	)		(0.00	)

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

F-15

10. COMMITMENTS AND CONTINGENCIES

Operating Commitment

The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of March 31, 2018 are payable as follows:

As of March 31,	Amount
2019	$	2,463
2020		-
Total minimum payments	$	2,463

Rental expense was $2,533 and $14,330 for the three months ended March 31, 2018 and 2017, respectively.

11. SUBSEQUENT EVENT

The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2018 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

******

F-16

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our unaudited consolidated financial statements for the three months ended March 31, 2018 and 2017, and notes thereto contained elsewhere in this Report, our annual report on Form 10-K for the twelve months ended September 30, 2017 and 2016 including the consolidated financial statements and notes thereto and our transition annual report on Form 10-KT for the transition period from October 1, 2017 to December 31, 2017, including the audited financial statements for the three months ended December 31, 2017 and for the twelve months ended September 30, 2017 and notes thereto. The following discussion and analysis contains forward-looking statements, which involve risks and uncertainties. Our actual results may differ significantly from the results, expectations and plans discussed in these forward-looking statements. See “Cautionary Note Concerning Forward-Looking Statements.”

Introduction

Currently, we are a holding company operating through our wholly owned subsidiary, American BriVision Corporation (“BriVision”), a Delaware corporation. BriVision was incorporated in 2015 in the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs. Following the Share Exchange (as described herein below), we have abandoned our prior business plan and we are now pursuing BriVision’s historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.

Share Exchange

On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among the Company, BriVision, Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People Republic of China (“Euro-Asia”), being the owners of record of 52,336,000 shares of common stock of the Company, and the persons listed in Exhibit A thereof (the “BriVision Shareholders”), being the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 52,936,583 shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 51,945,225 shares of the Company’s common stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represents 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.

Because of the consummation of the Share Exchange, as of February 8, 2016, BriVision is our wholly owned subsidiary and its shareholders owned approximately 79.70% of our issued and outstanding common stock.

Collaborative Agreements

BioLite, Inc.:

We currently have sole licensing rights to the drug and therapeutic use for six products developed by BioLite, Inc. (“BioLite”). BioLite is a botanical new drug developer incorporated under the laws of Taiwan in 2006. On December 29, 2015, BriVision entered into a Collaborative Agreement (the “Collaborative Agreement”) with BioLite, which was amended on May 6, 2016. On January 12, 2017, BriVision and BioLite entered into an addendum (the “Addendum”) to the Collaborative Agreement (collectively, the “Latest Collaborate Agreement”). Our chairman and interim CFO, Eugene Jiang, is a director of BioLite, and therefore BioLite is considered a related party.

As of March 31, 2018, two milestones payments, pursuant to the Collaborative Agreement, were made:

An upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the Collaborative Agreement, was paid by us upon execution of the Collaborative Agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we agreed to pay a Milestone Payment to BioLite of $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and share issuance were completed in June 2016.

On February 22, 2017, the Company remitted the payment of 6.5% of total payment, $6,500,000, to BioLite, with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.00 per share, for an aggregate number of 2,925,000 shares, for the first IND submitted in March 2016.

Rgene Corporation:

On May 26, 2017, we entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation, a corporation incorporated under the laws of Taiwan (“Rgene”), to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum.

Under the terms of the Co-Dev Agreement, Rgene is obligated to pay the Company up to a total of $3,000,000 in cash or stock by August 15, 2017 in three installments. As of this periodic report, we have received $450,000 in cash. We are still in discussion with Rgene with respect to the schedule of the payment of the outstanding balance. The Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both Parties. For more information about the Co-Dev Agreement, please refer to the current report on Form 8-K we filed on May 30, 2017.

As of date of this report, no net licensing income and/or net sales profit has occurred.

BioFirst Corporation:

On July 24, 2017, we entered into a collaborative agreement (the “BioFirst Agreement”) with BioFirst Corporation (“BioFirst”), a corporation incorporated under the laws of Taiwan, pursuant to which BioFirst granted us the global license for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company as Eugene Jiang is one of the directors and common stock shareholders of BioFirst.

According to the BioFirst Agreement, we will co-develop and commercialize the Product with BioFirst and pay BioFirst $3,000,000 (the “Total Payment”) in cash or stock by September 30, 2018 in two installments. An upfront payment of $300,000, representing 10% of the Total Payment due under the Collaborative Agreement, was paid by us upon signing of the Collaborative Agreement. The Company is entitled to receive 50% of the future net licensing income. For more information about the BioFirst Agreement, please refer to the current report on Form 8-K we filed on July 24, 2017.

Operations

BriVision selects potential drug candidates (including but not limited to botanical drugs) from different research institutes, starts to develop them from pre-clinical stage (including all CMC process and animal study) to clinical study stage. When the phase II clinical trial is finished and the efficacy is approved, we will have reached the “proof of concept” stage. We plan to out license our drugs to pharmaceutical companies, coordinate with them to develop and enhance the drug candidates.

Revenue Generation

Most of our licensed products are still under development and trial stage. During the three months ended March 31, 2018 and 2017, we generated $0 in revenues.

Research and Development

During the three months for the period ended March 31, 2018 and 2017, we spent approximately $ 45,055 and $ 25,150 on research and development, respectively which consisted primarily of research and development payroll expenses. Such payroll expenses were settled in both cash and common stock issued by the Company.

Critical Accounting Policies and Estimates

We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this “Management’s Discussion and Analysis of Financial Condition and Results of Operation.”

Basis of Presentation

Fiscal Year

Reclassifications

Forward Stock split

Use of Estimates

Fair Value Measurements

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.

Cash and Cash Equivalents

Concentration of Credit Risk

Receivable from Collaboration Partners

Research and Development Expenses

Stock-based Compensation

Income Taxes

For the three months ended March 31, 2018 and 2017, the Company’s income tax expense amounted $1,850 and $830, respectively.

Loss Per Share of Common Stock

Commitments and Contingencies

Recent Accounting Pronouncements

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”).To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

Limited Operating History; Need for Additional Capital

There is limited historical financial information about us upon which to base an evaluation of our performance. As of the date of this filing, we have not generated any revenues from operations. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of successful new drug development operations, including limited capital resources, possible delays in reaching certain FDA milestones and licensing process. We do not believe we have sufficient funds to operate our business for the next 12 months.

We have no assurance that future financing will be available to us on acceptable terms, or at all. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing could result in additional dilution to existing shareholders.

If we are unable to raise additional capital to maintain our operations in the future, we may be unable to carry out our full business plan or we may be forced to cease operations.

The following discussion and analysis should be read in conjunction with the audited financial statements of the Company for the period ended September 30, 2017 and 2016 and accompanying notes that appear in our Annual Report on Form 10-K/A Amendment No.2, as filed with the Securities and Exchange Commission on May 22, 2017 and the financial statements included in this Report.

Results of Operation

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities, but we cannot guarantee that we will be able to achieve the same.

Results of Operations — Three Months Ended March 31, 2018 Compared to March 31, 2017.

The following table presents, for the three months indicated, our consolidated statements of operations information.

	Three months ended March 31, 2018			Three months ended March 31, 2017
	(Unaudited)
REVENUE	$	-		$	-

COST OF REVENUE		-			-

GROSS LOSS		-			-

OPERATING EXPENSES

Selling, general and administrative expenses		175,864			208,315
Research and development expenses		45,055			25,150
Stock based compensation		5,626			3,376

NET LOSS FROM OPERATIONS		(226,545	)		(236,841	)

OTHER (EXPENSES) INCOME, NET
Interest Expense		(33,645	)		(19,000	)
Total Other (Expenses) Income		(33,645	)		(19,000	)

NET LOSS BEFORE TAXES		(260,190	)		(255,841	)
Provision income tax		1,850			830
NET LOSS		(262,040	)		(256,671	)

Revenues. We generated zero in revenues and zero in cost of sales for the three months ended March 31, 2018 and 2017, respectively.

Operating Expenses. Our operating expenses were $226,545 in the three months ended March 31, 2018 as compared to $236,841 in the three months ended March 31, 2017. Our total operating expenses did not change substantially during the three-month periods ended March 31, 2018 and 2017. Our research and development expenses increased by $19,905 or approximately 80% primarily because we increased a research project related to Vitreous Substitute for Vitrectomy.

Interest Expense. The interest expense was $33,645 in the three months ended March 31, 2018 as compared to $19,000 in the three months ended March 31, 2017. The increase is primarily due to the increase of loans the Company borrowed from BioFirst.

Net Loss. The net loss was $262,040 for the three months ended March 31, 2018 compared to $256,671 for the three months ended March 31, 2017. The Company’s net loss did not change substantially during the three months ended March 31, 2018 and 2017.

Liquidity and Capital Resources

Working Capital

	As of March 31, 2018 ($)			As of December 31, 2017 ($)
	(Unaudited)
Current Assets		2,555,675			2,643,332
Current Liabilities		4,489,004			4,400,247
Working Capital (deficit)		(1,933,329	)		(1,756,915	)

Cash Flows

Cash Flow from Operating Activities

During the three months ended March 31, 2018 and 2017, the net cash used in operating activities were $137,657 and $862,235, respectively. The decrease in the amount of $724,578 is primarily due to the Company paying off due to related parties in the amount of approximately $650,000 during the three month ended March 31, 2017 and the increase in accrued expenses (primarily consisting of payroll expenses) in the amount of approximately $30,000 from December 31, 2017 to March 31, 2018.

Cash Flow from Investing Activities

During the three months ended March 31, 2018 and 2017, there was no net cash used in or generated from investing activities.

Cash Flow from Financing Activities

During the three months ended March 31, 2018 and 2017, the Company borrowed $50,000 from YuanGene and $950,000 from BioFirst to meet its working capital needs, respectively.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Smaller reporting companies are not required to provide the information required by this item.

ITEM 4.

CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and interim Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on their evaluation, our management, including our Chief Executive Officer and interim Chief Financial Officer, concluded that our disclosure controls and procedures are not effective as of March 31, 2018.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures is also based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal controls over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect our internal controls over financial reporting.

PART II. - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

Nil.

ITEM 1A.

RISK FACTORS.

Smaller reporting companies are not required to provide the information required by this item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On March 28, 2018, the Company issued 4,828 shares of common stock of the Company at $1.60 per share for compensation of $7,725 to Mr. Kameyama in connection with the consulting agreement with Mr. Kameyama.

On March 28, 2018, the Company issued 50,000 shares of the Company’s common stock at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.

On March 28, 2018, the Company issued 75,000 shares of the Company’s common stock at $1.60 per share for total value of $120,000 to Kimho in connection with the Kimho Agreement.

On March 28, 2018, the Company also issued an aggregate of 50,000 shares of the Company’s common stock at $1.60 per share for three officers’ salaries in the aggregate amount of $80,000 pursuant to the respective employment agreements.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

Nil.

ITEM 4.

MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.

OTHER INFORMATION.

On January 31, 2018, the Company entered into an agreement and plan of merger (the “Merger Agreement”) with BioLite Holding, Inc. (“BioLite”), a Nevada corporation, BioKey, Inc. (“BioKey”), a California corporation, BioLite Acquisition Corp. (“Merger Sub 1”), a Nevada corporation and wholly-owned subsidiary of the Company, and BioKey Acquisition Corp. (“Merger Sub 2”), a California corporation and wholly-owned subsidiary of the Company. Pursuant to the Merger Agreement, on or before the Closing of the Merger, each issued and outstanding share of BioLite shall be converted into the right to receive one point eighty-two (1.82) validly issued, fully-paid and non-assessable shares of the Company and all shares of BioLite shall be cancelled and cease to exist. Also on or before the Closing of the Merger, each issued and outstanding share of BioKey shall be converted into the right to receive one (1) validly issued, fully-paid and non-assessable share of the Company and all shares of BioKey shall be cancelled and cease to exist. The description of the Merger Agreement is not purported to be complete and a copy of such Agreement was filed with the SEC on a current report on Form 8-k on February 5, 2018 and is incorporated by reference herein.

ITEM 6.

EXHIBITS

The following exhibits are filed herewith:

Exhibit No.		Description

31.1		Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	American BriVision (Holding) Corporation

Dated: May 15, 2018	By:	/s/ Howard Doong
		Howard Doong
		Chief Executive Officer (Principal Executive Officer)

Dated: May 15, 2018	By:	/s/ Eugene Jiang
		Eugene Jiang
		Interim Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 f10q0318ex31-1_americanbriv.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Howard Doong, Chief Executive Officer of American BriVision (Holding) Corporation. (the “Company”), certify that:

1. I have reviewed this Quarterly Report on Form 10-Q (this “Report”) of the Company;

2. Based on my knowledge, this Report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 3a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

(d)

Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2018

/s/ Howard Doong
Howard Doong, CEO

EX-31.2 3 f10q0318ex31-2_americanbriv.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002

I, Eugene Jiang, interim Chief Financial Officer of American BriVision (Holding) Corporation. (the “Company”), certify that:

1. I have reviewed this Quarterly Report on Form 10-Q (this “Report”) of the Company;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 15, 2018

/s/ Eugene Jiang
Eugene Jiang Interim Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 f10q0318ex32-1_americanbriv.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American BioVision (Holding) Corporation (the “Company”) on Form 10-Q for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2018

/s/ Howard Doong

Howard Doong,

Chief Executive Officer

EX-32.2 5 f10q0318ex32-2_americanbriv.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2018

/s/ Eugene Jiang

Eugene Jiang

Interim Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-101.INS 6 abvc-20180331.xml XBRL INSTANCE FILE 0001173313 2017-10-01 2017-12-31 0001173313 2018-03-28 0001173313 2017-12-31 0001173313 us-gaap:CollaborativeArrangementMember 2015-12-29 0001173313 abvc:CollaborativeArrangementOneMember 2016-08-26 0001173313 abvc:BioliteIncMember 2017-12-31 0001173313 abvc:BioFirstCorporationMember 2017-12-31 0001173313 abvc:AsiangeneCorporationMember 2017-12-31 0001173313 abvc:YuangeneCorporationMember 2017-12-31 0001173313 abvc:CodevelopmentagreementMember 2017-05-26 0001173313 us-gaap:CollaborativeArrangementMember 2017-07-24 0001173313 abvc:EugeneJiangMember 2017-12-31 0001173313 abvc:CodevelopmentagreementMember 2017-12-31 0001173313 abvc:CollaborativeArrangementOneMember 2016-10-01 2017-09-30 0001173313 us-gaap:CollaborativeArrangementMember 2016-05-05 2016-05-06 0001173313 abvc:BioliteIncMember 2016-08-01 2016-08-26 0001173313 abvc:CollaborativeArrangementOneMember 2017-02-01 2017-02-28 0001173313 us-gaap:CollaborativeArrangementMember 2017-07-01 2017-07-24 0001173313 abvc:CodevelopmentagreementMember 2016-10-01 2017-09-30 0001173313 abvc:CodevelopmentagreementMember 2017-10-01 2017-12-31 0001173313 abvc:ShareExchangeAgreementThreeMember 2016-02-04 2016-02-08 0001173313 abvc:CollaborativeArrangementOneMember 2017-09-01 2017-09-25 0001173313 abvc:LoanAgreementMember 2017-01-26 0001173313 abvc:LoanAgreementMember 2017-01-01 2017-01-26 0001173313 abvc:AsiangeneCorporationMember 2017-10-01 2017-12-31 0001173313 abvc:BioLiteMember 2017-10-01 2017-12-31 0001173313 2017-12-01 2017-12-22 0001173313 abvc:BioliteIncMember 2016-08-26 0001173313 2016-03-20 2016-03-21 0001173313 2015-10-30 0001173313 abvc:ShareExchangeAgreementTwoMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementFourMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementMember 2016-02-04 2016-02-08 0001173313 abvc:ShareExchangeAgreementOneMember 2016-02-04 2016-02-08 0001173313 abvc:EquityIncentivePlanMember 2016-02-01 2016-02-17 0001173313 abvc:ShareExchangeAgreementTwoMember 2016-02-08 0001173313 abvc:ShareExchangeAgreementFourMember 2016-02-08 0001173313 us-gaap:CollaborativeArrangementMember 2016-05-06 0001173313 us-gaap:CollaborativeArrangementMember 2017-02-28 0001173313 abvc:CollaborativeArrangementOneMember 2017-02-28 0001173313 abvc:CodevelopmentagreementMember 2017-05-01 2017-05-26 0001173313 abvc:CollaborativeArrangementOneMember 2016-03-31 0001173313 abvc:CollaborativeArrangementOneMember 2016-03-01 2016-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2016-09-15 2016-10-02 0001173313 2018-01-01 2018-03-31 0001173313 2018-05-15 0001173313 2018-03-31 0001173313 2017-01-01 2017-03-31 0001173313 2016-12-31 0001173313 2017-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2015-12-24 2015-12-29 0001173313 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0001173313 us-gaap:CollaborativeArrangementMember 2018-03-31 0001173313 abvc:CodevelopmentagreementMember 2017-09-30 0001173313 abvc:CodevelopmentagreementMember 2017-01-01 2017-12-31 0001173313 abvc:BioliteIncMember 2018-01-01 2018-03-31 0001173313 abvc:BioFirstCorporationMember 2018-01-01 2018-03-31 0001173313 abvc:RgeneCorporationMember 2018-01-01 2018-03-31 0001173313 abvc:YuangeneCorporationMember 2018-01-01 2018-03-31 0001173313 abvc:AsiangeneCorporationMember 2018-01-01 2018-03-31 0001173313 abvc:EugeneJiangMember 2018-01-01 2018-03-31 0001173313 abvc:BioFirstCorporationMember 2018-03-31 0001173313 abvc:AsiangeneCorporationMember 2018-03-31 0001173313 abvc:YuangeneCorporationMember 2018-03-31 0001173313 abvc:EugeneJiangMember 2018-03-31 0001173313 abvc:BioLiteMember 2018-01-01 2018-03-31 0001173313 abvc:BioFirstCollaborativeAgreementMember 2017-09-25 0001173313 abvc:AsiangeneCorporationMember 2017-01-01 2017-03-31 0001173313 abvc:YuangeneCorporationMember 2017-01-01 2017-12-31 0001173313 abvc:YuangeneCorporationMember 2018-01-02 2018-01-18 0001173313 abvc:CodevelopmentagreementMember 2018-01-01 2018-03-31 0001173313 us-gaap:BoardOfDirectorsChairmanMember 2018-01-01 2018-03-31 0001173313 us-gaap:BoardOfDirectorsChairmanMember 2017-01-01 2017-12-31 0001173313 abvc:ConsultingAgreementMember 2018-03-28 0001173313 abvc:EuroAsiaInvestmentAndFinanceCorpLtdMember 2018-03-28 0001173313 abvc:KimhoConsultantsCoLtdMember 2018-03-28 0001173313 abvc:YuangeneCorporationMember 2017-01-01 2017-03-31 0001173313 abvc:BioliteIncMember 2018-03-31 0001173313 abvc:CodevelopmentagreementMember 2017-09-30 0001173313 abvc:CodevelopmentagreementMember 2017-05-26 0001173313 abvc:CodevelopmentagreementMember 2018-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 213926475

2550000

2643332

2555675

2643332

2555675

4229320

100000000

109220

3957000

160000

3000

3000000

100

450000

4286320

100000000

3964000

160000

53000

100

109220

3000000

450000

213747

213927

13805936

13891382

3000000

50000

213746647

213926475

4828

50000

75000

213746647

213926475

45055

25150

5626

3376

900000

1468750

5850000

3000000

2550000

562500

2925000

2600000 650000 1933329

3000000

10000000

950000

The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.

950000

160000

950000

50000

160000

17460

17960

1200

7000 109220 14000 3000 109220 3000 50000 100 100

0.00

1850

830

1850 830

1850

830

29075 26000 17460 19160

110800

141500

170927

202684

33645

19000

1200

3945

-33645

-19000

-260190

-255841

1850

830

213754639

212056647

13592

12961

2018-02-01

3000000

360000000

1.60

0.001

1.60

1 to 3.141

350000

52936583 51945225 65431144 52336000 52936583 50000 166273921 163159952 205519223 164387376 166273921 157050

0.7970

1.00

1.60

2350000

0.2536-for-1

1.60

2.0

2.00

3000000

6500000

15000000

0.50 0.50 0.065 0.035 0.15 650000 The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. American BriVision (Holding) Corp 0001173313 ABVC false --12-31 10-Q 2018-03-31 2018 Q1 Smaller Reporting Company

-1756915

-1933329

-15776598

-16038638

4400247

4489004

-0.00

-262040

-256671

-226545

-236841

175864

208315

80000 5850000

1850

830

31945

9500

-87657

87765

50000

950000

50000

950000

-137657

-862235

7000

-650000

111757

41060

Basis of Presentation   The accompanying consolidated unaudited financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.   This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.

Fair Value Measurements   The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.   Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.   ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: left; padding: 0; text-indent: 0; width: 4%; vertical-align: top">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr> </table>   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: justify; padding: 0; text-indent: 0; width: 4%">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</td></tr> </table>   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: justify; padding: 0; text-indent: 0; width: 4%">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</td></tr> </table>   There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.

Receivable from Collaboration Partners   Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued consulting fee</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">29,075</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional service fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,592</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest expense – related party(Note 6)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,460</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued payroll</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">141,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,063</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">202,684</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">170,927</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

0.50

93332

5675

18645

106410

3063

<table cellspacing="0" cellpadding="0" style="font: 12pt times new roman, times, serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px"> </td><td style="vertical-align: top; width: 24px">●</td><td style="text-align: justify">upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top">●</td><td style="text-align: justify">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr></table><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px"> </td><td style="vertical-align: top; width: 24px">●</td><td style="text-align: justify">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top">●</td><td style="text-align: justify">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top">●</td><td style="text-align: justify">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top">●</td><td style="vertical-align: bottom">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. </td></tr></table>

3500000

100000000

3000000

450000

3000000

0.2536-for-1

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioLite, Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">109,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">109,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,964,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,957,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">AsianGene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">YuanGene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Eugene Jiang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,286,320</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,229,320</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene Entity controlled by controlling beneficiary shareholder of YuanGene Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene Controlling beneficiary shareholder of the Company Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene Chairman, interim CFO and former President

Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of March 31, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019.

Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 17, 2017.

5000

15000

80000 7725 80000 120000

8. INCOME TAX   The Company files income tax returns in the U.S. federal jurisdiction, and various state and local jurisdictions. The Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2013.   On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of March 31, 2018 and December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at March 31, 2018 and December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the three months ended March 31, 2018 and for the year ended December 31, 2017. The provisional remeasurement amount is anticipated to change as data becomes available allowing more accurate scheduling of the deferred tax assets and liabilities primarily related to net operating loss carryover.   Components of income tax (benefits) for the three months ended March 31, 2018 and 2017 are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="22" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Federal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">State</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Federal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">State</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">Current</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">              -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">830</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">830</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,850</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,850</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">830</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">830</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Significant components of the Company’s deferred tax accounts at March 31, 2018 and December 31, 2017:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">Deferred Tax Account - noncurrent:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2018</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 10pt">Tax losses carryforwards</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">647,960</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594,501</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(647,960</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(594,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; padding-left: 30pt">Total deferred tax account - noncurrent</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   The difference between the effective rate reflected in the provision for income taxes on loss before taxes and the amounts determined by applying the applicable statutory U.S. tax rate are analyzed below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Statutory federal tax benefit, net of state tax effects</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">19</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.84</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.84</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Nondeductible/nontaxable items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.84</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(38.84</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Effective income tax rate</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="22" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Federal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">State</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Federal</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">State</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%">Current</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">         -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">              -</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">830</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">830</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,850</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,850</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">830</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">830</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

647960

594501

647960

594501

0.31

0.19

0.0884

0.01

0.02

-0.3884

-0.2484

0.00

0.01

9. LOSS PER SHARE   Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31, 2018 and 2017.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(262,040</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(256,671</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted-average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">213,754,639</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">212,056,647</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">213,754,639</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">212,056,647</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table>   Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(262,040</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(256,671</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted-average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">213,754,639</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">212,056,647</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">213,754,639</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">212,056,647</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">(0.00</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table>

213754639

212056647

213754639

212056647

-0.00

10. COMMITMENTS AND CONTINGENCIES   Operating Commitment   The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of March 31, 2018 are payable as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left">As of March 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,463</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total minimum payments</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,463</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Rental expense was $2,533 and $14,330 for the three months ended March 31, 2018 and 2017, respectively.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left">As of March 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,463</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total minimum payments</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,463</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

2463

2533

14330

11. SUBSEQUENT EVENT   The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of March 31, 2018 have been incorporated into these financial statements and there are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

2643332

2555675

5626 3376

H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of March 31, 2018 and December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at March 31, 2018 and December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the three months ended March 31, 2018 and for the year ended December 31, 2017.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 35%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Name of entity or Individual</td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="width: 64%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">Relationship with the Company and its subsidiaries</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">BioLite Inc. (the “BioLite”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">BioFirst Corporation (the “BioFirst”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Rgene Corporation (the “Rgene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">YuanGene Corporation (the “YuanGene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Controlling beneficiary shareholder of the Company</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">AsianGene Corporation (the “AsianGene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Eugene Jiang </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Chairman, interim CFO and former President </td></tr> </table>

1. ORGANIZATION AND DESCRIPTION OF BUSINESS   American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (the “BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. BriVision had no predecessor operations prior to its formation on July 21, 2015.   Reverse Merger   On February 8, 2016, a Share Exchange Agreement (the “Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation, American BriVision Corporation (“BriVision”), and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”).   Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the “Merger”).   Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583pre-stock split) common shares of the Company and BriVision has become a wholly owned subsidiary of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223(65,431,144 pre-stock split) shares of Company’s common stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision has become a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.   Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.   Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs.  The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets.   Accounting Treatment of the Reverse Merger   For financial reporting purposes, the Share Exchange represented a “reverse merger” rather than a business combination and BriVision was deemed the accounting acquirer in the transaction. The Share Exchange was being accounted for as a reverse-merger and recapitalization. BriVision was the acquirer for financial reporting purposes and the Company was the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange were those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange included the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation   The accompanying consolidated unaudited financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.   This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars.   Fiscal Year   The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.   Reclassifications   Certain classifications have been made to the prior year financial statements to conform to the current year presentation. The reclassification had no impact on previously reported net loss or accumulated deficit.   Forward Stock split   On March 21, 2016, the Board of Directors of the Company approved an amendment to its Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to the Articles of Incorporation.   Fair Value Measurements   The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements.  ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.   Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.   ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: left; padding: 0; text-indent: 0; width: 4%; vertical-align: top">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</td></tr> </table>   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: justify; padding: 0; text-indent: 0; width: 4%">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</td></tr> </table>   <table cellpadding="0" cellspacing="0" border="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: top"> <td style="padding: 0; text-indent: 0; width: 4%"> </td> <td style="text-align: justify; padding: 0; text-indent: 0; width: 4%">-</td> <td style="text-align: justify; padding: 0; text-indent: 0">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</td></tr> </table>   There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.   Cash and Cash Equivalents   The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2018 and December 31, 2017, the Company’s cash and cash equivalents amounted $5,675 and $93,332, respectively. The Company’s cash deposits are held in financial institutions located in both Taiwan and the United States of America where there are currently regulations mandated on obligatory insurance of bank accounts. The Company believes these financial institutions are of high credit quality.   Concentration of Credit Risk   The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes. Concentration of credit risk with respect to trade and notes receivables is limited due to the wide variety of customers and markets in which the Company transacts business, as well as their dispersion across many geographical areas. The Company performs ongoing credit evaluations of its customers and generally does not require collateral, but does require advance deposits on certain transactions.   Receivable from Collaboration Partners   Receivable from collaboration partners is stated at carrying value less estimates made for doubtful receivables. An allowance for impairment of receivable from collaboration partners is established if the collection of a receivable becomes doubtful. Such receivable becomes doubtful when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the receivable is impaired. The amount of the allowance is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. An impairment loss is recognized in the statement of operations, as are subsequent recoveries of previous impairments.   Research and Development Expenses   The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. Stock-based Compensation   The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2018 and 2017.   The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 718 “Compensation-Stock Compensation” and ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $5,626 and $3,376 for the three months ended March 31, 2018 and 2017, respectively.   Income Taxes   The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.   Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the three months ended March 31, 2018 and 2017. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.   On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”). In accordance with this guidance, the Company’s financial results reflect provisional amounts for those specific income tax effects of the 2017 Tax Act for which the accounting under ASC Topic 740 is incomplete but a reasonable estimate could be determined. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.   For the three months ended March 31, 2018 and 2017, the Company’s income tax expense amounted to $1,850 and $830, respectively.   Loss Per Share of Common Stock   The Company reports loss per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.   Commitments and Contingencies   The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.   Recent Accounting Pronouncements   In February 2016, the FASB issued ASU No. 2016-02, “Leases.” The core principle of the ASU is that a lessee should recognize the assets and liabilities that arise from its leases other than those that meet the definition of a short-term lease. The ASU requires extensive qualitative and quantitative disclosures, including with respect to significant judgments made by management. Subsequently, the FASB issued ASU No. 2017-13, in September 2017 and ASU No. 2018-01, in January 2018, which amends and clarifies ASU 2016-02. The ASU will be effective for the Company beginning January 1, 2019, including interim periods in the fiscal year 2019. Early adoption is permitted. The Company is in the process of determining the method of adoption and assessing the impact of this ASU on its consolidated results of operations, cash flows, financial position and disclosures.   In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients and ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting . In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. ASU 2016-10 clarifies the following two aspects of ASU 2014-09: identifying performance obligations and licensing implementation guidance. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. ASU 2016-12 provides clarification to Topic 606 on how to assess collectability, present sales tax, treat noncash consideration, and account for completed and modified contracts at the time of transition. ASU 2016-12 clarifies that an entity retrospectively applying the guidance in Topic 606 is not required to disclose the effect of the accounting change in the period of adoption. Additionally, ASU 2016-20 clarifies certain narrow aspects within Topic 606 including its scope, contract cost accounting, and disclosures. The new guidance requires enhanced disclosures, including revenue recognition policies to identify performance obligations to customers and significant judgments in measurement and recognition. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the overall impact that ASU 2014-09 and its related amendments will have on the Company’s financial statements.   On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”).To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.   In February 2018, the FASB issued Accounting Standards Update No. 2018-02 (ASU 2018-02), Income Statement - Reporting Comprehensive Income (Topic 220). The guidance in ASU 2018-02 allows an entity to elect to reclassify the stranded tax effects related to the Tax Cuts and Jobs Act (the Tax Act) of 2017 from accumulated other comprehensive income into retained earnings. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its Consolidated Financial Statements.

Stock-based Compensation   The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation”. Total employee stock-based compensation expenses were $0 for the three months ended March 31, 2018 and 2017.   The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 718 “Compensation-Stock Compensation” and ASC Topic 505-50 “Equity-Based Payments to Non-Employees” which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $5,626 and $3,376 for the three months ended March 31, 2018 and 2017, respectively.

4. COLLABORATIVE AGREEMENTS   Collaborative agreement with BioLite Inc., a related party   On December 29, 2015, American BriVision Corporation entered into a collaborative agreement (the “BioLite Collaborative Agreement”) with BioLite Inc. (the “BioLite”), a related party (See Note 6), pursuant to which BioLite granted BriVision sole licensing rights for drug and therapeutic use of five products, including BLI-1005 CNS-Major Depressive Disorder, BLI-1008 CNS-Attention Deficit Hyperactivity Disorder, BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1, BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer, and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in the U.S.A and Canada. Under the BioLite Collaborative Agreement, BriVision is obliged to pay up to a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">● </td> <td style="width: 92%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">●</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">●</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">●</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">●</td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">●</td> <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. </td></tr> </table>   This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.   Pursuant to the BioLite Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the BioLite Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company agreed to pay the Milestone Payment to BioLite with $2,600,000 in cash and $900,000 in the form of newly issued shares of its common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016.   Pursuant to the BioLite Collaborative Agreement, the 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of its common stock, at the price of $2.00 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017.   Pursuant to the BioLite Collaborative Agreement, the 15% of total payment, $15,000,000 shall be made at the completion of first phase II clinical trial. As of March 31, 2018, the first phase II clinical trial research has not been completed yet.    The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount is fully expensed as research and development expense when incurred.   On January 12, 2017, the Company entered into an Addendum (the “Addendum”) to the BioLite Collaborative Agreement which was previously entered into with BioLite. Pursuant to the Addendum, the Company and BioLite agreed to include one more product, namely, “Maitake Combination Therapy” as one of the Products defined in the BioLite Collaborative Agreement (the “Sixth Product’) and defined the Territory of the Sixth Product to be worldwide and restate the Territory of the Five Products to be the U.S.A and Canada.   Co-Development agreement with Rgene Corporation, a related party   On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation (the “Rgene”), a related party under common control by the controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 6). Pursuant to the Co-Dev Agreement, BriVison and Rgene agreed to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene should pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision’s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. Besides the $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development cost shall be equally shared by both BriVision and Rgene.   On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended September 30, 2017, the Company has received $450,000 in cash. As of the date of this report, the Company is still in discussion with Rgene with respect to the schedule of the outstanding balance of $2,550,000.   Collaborative agreement with BioFirst Corporation, a related party   On July 24, 2017, American BriVision Corporation entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and common stock shareholders of BioFirst (See Note 7).   Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst’s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.   On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. No payment has been made by the Company as of the date of this report. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence the entire amount of $3,000,000 has been fully expensed as research and development expense during the year ended September 30, 2017.

6. RELATED PARTIES TRANSACTIONS   The related parties of the company with whom transactions are reported in these financial statements are as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="width: 35%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Name of entity or Individual</td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="width: 64%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify; text-indent: 0">Relationship with the Company and its subsidiaries</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">BioLite Inc. (the “BioLite”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">BioFirst Corporation (the “BioFirst”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Rgene Corporation (the “Rgene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">YuanGene Corporation (the “YuanGene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Controlling beneficiary shareholder of the Company</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">AsianGene Corporation (the “AsianGene”)</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">Eugene Jiang </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"> </td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: justify">Chairman, interim CFO and former President </td></tr> </table>   Due to related parties   Amount due to related parties consisted of the following as of the periods indicated:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">BioLite, Inc.</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">109,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">109,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">BioFirst Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,964,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,957,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">AsianGene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">YuanGene Corporation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Eugene Jiang</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,286,320</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,229,320</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Related party transactions   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(1)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2018 and December 31, 2017, BioLite has advanced an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(2)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">On January 26, 2017, the Company and BioFirst entered into a loan agreement for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on February 1, 2018. On February 2, 2018, the Company and BioFirst agreed to extend the maturity date of loan to February 1, 2019 with the same terms of the original loan agreement. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $950,000 and accrued interest is $17,960 and $17,460 (See Note 5). Interest expenses in connection with this loan were $28,500 and $19,000 for the three months ended March 31, 2018 and 2017, respectively.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(3)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 24, 2017, BriVision entered into a collaborative agreement (the “BioFirst Collaborative Agreement”) with BioFirst (See Note 4). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded full amount of $3,000,000 due to BioFirst.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(4)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2018 and December 31, 2017, BioFirst has advanced in an aggregate amount of $14,000 and $7,000 to the Company for working capital purposes, respectively. The advances bear 0% interest rate and are due on demand.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(5)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">In September 2017, AsianGene entered an investment and equity transfer agreement (the “Investment and Equity Transfer Agreement”) with Everfront Biotech Inc. (the “Everfront”), a third party. Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of March 31, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $160,000. Interest expenses in connection with this loan were $3,945 and $0 for the three months ended March 31, 2018 and 2017, respectively.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(6)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2018 and December 31, 2017, YuanGene Corporation has advanced an aggregate amount of $3,000 to the Company for working capital purposes. The advances bear 0% interest rate and are due on demand.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(7)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">On January 18, 2018, the Company and YuanGene entered into a loan agreement for a total of $50,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 17, 2019. As of March 31, 2018 and December 31, 2017, the outstanding loan balance is $50,000 and $0, and accrued interest is $1,200 and $0 (See Note 5), respectively. Interest expenses in connection with this loan were $1,200 and $0 for the three months ended March 31, 2018 and 2017, respectively.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(8)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2018 and December 31, 2017, the Chairman of the Company has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(9)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 4). As of March 31, 2018 and December 31, 2017, the Company has received an aggregate amount of $450,000 in cash and has recorded $2,550,000 as receivable from collaboration partners. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017.</td></tr></table>   <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 4%; font: 10pt Times New Roman, Times, Serif">(10)</td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2017, the Company entered an operating lease agreement with AsianGene for an office space in Taiwan for the period from October 1, 2016 to July 31, 2017. The monthly base rent is approximately $5,000. Rent expenses under this lease agreement amounted to $0 and $15,000 for the three months ended March 31, 2018 and 2017, respectively.</td></tr></table>

7. EQUITY   During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.   On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among American BriVision (Holding) Corporation (the “Company”), American BriVision Corporation (“BriVision”), Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing.  There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.   On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.   On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. As a result, all shares outstanding for all periods have been retroactively restated to reflect Company’s 1 to 3.141 forward stock split.   The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.   On May 6, 2016, the Company and BioLite agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.   On August 26, 2016, the Company issued 1,468,750 common stock shares of the Company, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering was $1.60. The net proceeds to the Company from the Offering were approximately $2,350,000. The proceeds may be used for general corporate purposes.    Pursuant to the BioLite Collaborative Agreement (See Note 4), BriVision is obliged to pay up to a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.00 per share, for an aggregate number of 2,925,000 shares.   On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks shall be calculated and issued in December every year. On October 1, 2017, the contract was extended for one year ending at September 30, 2018. On March 28, 2018, the Company issued 4,828 common stock shares of the Company at $1.60 per share in a total of $7,725 to Kameyama in connection with this consulting agreement.   On January 1, 2017, Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) and the Company entered into a one-year service agreement (the “Euro-Asia Agreement”) for the maintenance of the listing in the U.S. stock exchange market. On March 28, 2018, the Company issued 50,000 common stock shares of the Company at $1.60 per share in a total of $80,000 to Euro-Asia in connection with the Euro-Asia Agreement.   On January 1, 2017, Kimho Consultants Co., Ltd. (the “Kimho”) and the Company entered into a one-year service agreement (the “Kimho Agreement”) for the maintenance of the listing in the U.S. stock exchange market. On March 28, 2018, the Company issued 75,000 common stock shares of the Company at $1.60 per share in a total of $120,000 to Kimho in connection with the Kimho Agreement.   Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a stock-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which the commitments Kameyama, Euro-Asia, and Kimho for performance were rendered.   On March 28, 2018, the Company also issued an aggregate of 50,000 common stock shares of the Company at $1.60 per share for salaries in a total of $80,000 to three officers.

EX-101.SCH 7 abvc-20180331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Collaborative Agreements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Parties Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Income Tax link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Loss per Share link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Related Parties Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Income Tax (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Collaborative Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Parties Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Parties Transactions (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related Parties Transactions (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Income Tax (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Tax (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Income Tax (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 abvc-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 abvc-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 abvc-20180331_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] Collaborative Arrangement [Member] Collaborative Arrangement One [Member] Related Party Transaction [Axis] BioLite Inc [Member] BioFirst Corporation [Member] Asiangene Corporation [Member] Yuangene Corporation [Member] Co-Dev Agreement [Member] Eugene Jiang [Member] Legal Entity [Axis] Share Exchange Agreement Three [Member] Loan Agreement [Member] BioLite [Member] Share Exchange Agreement Two [Member] Share Exchange Agreement Four [Member] Share Exchange Agreement [Member] Share Exchange Agreement One [Member] Plan Name [Axis] Equity Incentive Plan [Member] Rgene Corporation [Member] BioFirst Collaborative Agreement [Member] Title of Individual [Axis] Chairman [Member] Consulting Agreement [Member] Euro-Asia Investment & Finance Corp Ltd [Member] Related Party [Axis] Kimho Consultants Co., Ltd [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets Current assets Cash Receivable from collaboration partners - related parties Total Current Assets Total Assets Liabilities and Equity Accrued expense Due to related parties Total Liabilities Commitments and Contingencies Stockholders' deficit Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,926,475 and 213,746,647 at March 31, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit Total Liabilities and Equity Common stock, par value Common stock, authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative expenses Research and development expenses Stock based compensation expenses Loss from operations Other income(expenses) Interest expense Total other expenses Loss from continuing operations before provision income tax Provision income tax Net Loss and Comprehensive Loss Net loss per share Basic and diluted Weighted average number of common shares outstanding Basic and diluted Statement of Cash Flows [Abstract] Cash flows from operating activities Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Change in operating assets and liabilities: Increase in accrued expenses and other current liabilities Increase (decrease) in due to related parties Net cash used in operating activities Cash flows from financing activities Borrowings from related parties Net cash provided by financing activities Effect of exchange rates on cash Net increase (decrease) in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information Interest expense paid Income taxes paid Non-cash financing and investing activities Common shares issued for due to related parties Common shares issued for employees Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern [Abstract] GOING CONCERN Collaborative Agreements COLLABORATIVE AGREEMENTS Payables and Accruals [Abstract] ACCRUED EXPENSES Related Party Transactions [Abstract] RELATED PARTIES TRANSACTIONS Equity [Abstract] EQUITY Income Tax Disclosure [Abstract] INCOME TAX Earnings Per Share [Abstract] LOSS PER SHARE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENT Basis of Presentation Fiscal Year Use of Estimates Reclassifications Forward Stock split Fair Value Measurements Cash and Cash Equivalents Concentration of Credit Risk Receivable from Collaboration Partners Research and Development Expenses Stock-based Compensation Income Taxes Loss Per Share of Common Stock Commitments and Contingencies Recent Accounting Pronouncements Schedule of accrued expenses Schedule of related party transactions Schedule of amount due to related party Summary of income tax (benefits) Schedule of deferred tax Schedule of statutory rate and effective rate reconciliation Schedule of loss per share Schedule of future minimum lease payments Statement [Table] Statement [Line Items] Organization and Description of Business (Textual) Common stock issued post-stock split Common stock issued pre-stock split Percentage of common shares issued and outstanding Percentage of issued share capital Common stock converted to exchange ratio Summary of Significant Accounting Policies (Textual) Forward split ratio Cash and cash equivalents Income tax expense Employee stock-based compensation expenses Non-employee stock-based compensation expenses Income taxes ultimate settlement, percentage Going Concern (Textual) Net loss Working capital deficiency Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Agreements (Textual) Description of payment settlement Amount received from BriVision Upfront payments Percentage of payments under collaborative agreement Milestone payments to BioLite in cash Common stock newly issued, value Common stock newly issued, shares Share price Licensing rights Accounts payable Company cash payments Research and development expense Outstanding balance Agreement, terms Accrued consulting fee Accrued professional service fees Accrued interest expense - related party(Note 6) Accrued payroll Accrued operating expenses Total BioLite Inc. [Member] YuanGene Corporation [Member] AsianGene Corporation [Member] Relationship with the Company and its subsidiaries, description Related Parties Transactions (Textual) Amount received from BriVision Total commitment Loan maturity date EX-101.PRE 11 abvc-20180331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 15, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	0001173313
Trading Symbol	ABVC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		213,926,475

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 5,675	$ 93,332
Receivable from collaboration partners - related parties	2,550,000	2,550,000
Total Current Assets	2,555,675	2,643,332
Total Assets	2,555,675	2,643,332
Liabilities and Equity
Accrued expense	202,684	170,927
Due to related parties	4,286,320	4,229,320
Total Liabilities	4,489,004	4,400,247
Commitments and Contingencies
Stockholders' deficit
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,926,475 and 213,746,647 at March 31, 2018 and December 31, 2017, respectively	213,927	213,747
Additional paid-in capital	13,891,382	13,805,936
Accumulated deficit	(16,038,638)	(15,776,598)
Total stockholders' deficit	(1,933,329)	(1,756,915)
Total Liabilities and Equity	$ 2,555,675	$ 2,643,332

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	360,000,000	360,000,000
Common stock, shares issued	213,926,475	213,746,647
Common stock, shares outstanding	213,926,475	213,746,647

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses
Selling, general and administrative expenses	175,864	208,315
Research and development expenses	45,055	25,150
Stock based compensation expenses	5,626	3,376
Loss from operations	(226,545)	(236,841)
Other income(expenses)
Interest expense	(33,645)	(19,000)
Total other expenses	(33,645)	(19,000)
Loss from continuing operations before provision income tax	(260,190)	(255,841)
Provision income tax	1,850	830
Net Loss and Comprehensive Loss	$ (262,040)	$ (256,671)
Net loss per share
Basic and diluted	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding
Basic and diluted	213,754,639	212,056,647

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net loss from continuing operations	$ (262,040)	$ (256,671)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	5,626	3,376
Change in operating assets and liabilities:
Increase in accrued expenses and other current liabilities	111,757	41,060
Increase (decrease) in due to related parties	7,000	(650,000)
Net cash used in operating activities	(137,657)	(862,235)
Cash flows from financing activities
Borrowings from related parties	50,000	950,000
Net cash provided by financing activities	50,000	950,000
Effect of exchange rates on cash
Net increase (decrease) in cash	(87,657)	87,765
Cash, beginning of period	93,332	18,645
Cash, end of period	5,675	106,410
Supplemental disclosure of cash flow information
Interest expense paid	31,945	9,500
Income taxes paid	1,850	830
Non-cash financing and investing activities
Common shares issued for due to related parties		5,850,000
Common shares issued for employees	$ 80,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Organization and Description of Business

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Reverse Merger

Because of the consummation of the Share Exchange, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock.

Accounting Treatment of the Reverse Merger

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Fiscal Year

Use of Estimates

Reclassifications

Forward Stock split

Fair Value Measurements

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.

Cash and Cash Equivalents

Concentration of Credit Risk

Receivable from Collaboration Partners

Research and Development Expenses

Stock-based Compensation

Income Taxes

For the three months ended March 31, 2018 and 2017, the Company’s income tax expense amounted to $1,850 and $830, respectively.

Loss Per Share of Common Stock

Commitments and Contingencies

Recent Accounting Pronouncements

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”).To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Going Concern

3 Months Ended

Mar. 31, 2018

Going Concern [Abstract]

GOING CONCERN

3. GOING CONCERN

XML 20 R9.htm IDEA: XBRL DOCUMENT

Collaborative Agreements

3 Months Ended

Mar. 31, 2018

Collaborative Agreements

COLLABORATIVE AGREEMENTS

4. COLLABORATIVE AGREEMENTS

Collaborative agreement with BioLite Inc., a related party

	●	upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.

	●	upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.

	●	upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.

	●	upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.

Co-Development agreement with Rgene Corporation, a related party

Collaborative agreement with BioFirst Corporation, a related party

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

ACCRUED EXPENSES

5. ACCRUED EXPENSES

Accrued expenses as of March 31, 2018 and December 31, 2017 consisted of:

	March 31, 2018		December 31, 2017
Accrued consulting fee	$	26,000	$	29,075
Accrued professional service fees		12,961		13,592
Accrued interest expense – related party(Note 6)		19,160		17,460
Accrued payroll		141,500		110,800
Accrued operating expenses		3,063		-
Total	$	202,684	$	170,927

XML 22 R11.htm IDEA: XBRL DOCUMENT

Related Parties Transactions

3 Months Ended

Mar. 31, 2018

RELATED PARTIES TRANSACTIONS

6. RELATED PARTIES TRANSACTIONS

The related parties of the company with whom transactions are reported in these financial statements are as follows:

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsianGene Corporation (the “AsianGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Chairman, interim CFO and former President

Due to related parties

Amount due to related parties consisted of the following as of the periods indicated:

	March 31,		December 31,
	2018		2017
BioLite, Inc.	$	109,220	$	109,220
BioFirst Corporation		3,964,000		3,957,000
AsianGene Corporation		160,000		160,000
YuanGene Corporation		53,000		3,000
Eugene Jiang		100		100
Total	$	4,286,320	$	4,229,320

Related party transactions

(1)	As of March 31, 2018 and December 31, 2017, BioLite has advanced an aggregate amount of $109,220 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

(2)

(3)

(4)	As of March 31, 2018 and December 31, 2017, BioFirst has advanced in an aggregate amount of $14,000 and $7,000 to the Company for working capital purposes, respectively. The advances bear 0% interest rate and are due on demand.

(5)

(6)	As of March 31, 2018 and December 31, 2017, YuanGene Corporation has advanced an aggregate amount of $3,000 to the Company for working capital purposes. The advances bear 0% interest rate and are due on demand.

(7)

(8)	As of March 31, 2018 and December 31, 2017, the Chairman of the Company has advanced in an aggregate amount of $100 to the Company for working capital purpose. The advances bear 0% interest rate and are due on demand.

(9)

(10)

XML 23 R12.htm IDEA: XBRL DOCUMENT

Equity

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

EQUITY

7. EQUITY

During October 2015, $350,000 of subscription receivable was fully collected from the shareholders.

On February17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees.

The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.

On March 28, 2018, the Company also issued an aggregate of 50,000 common stock shares of the Company at $1.60 per share for salaries in a total of $80,000 to three officers.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Income Tax

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAX

8. INCOME TAX

Components of income tax (benefits) for the three months ended March 31, 2018 and 2017 are as follows:

	For the Three Months Ended March 31,
	2018						2017
	Federal		State		Total		Federal		State		Total
Current	$	-	$	1,850	$	1,850	$	-	$	830	$	830
Deferred		-		-		-		-		-		-
	$	-	$	1,850	$	1,850	$	-	$	830	$	830

Significant components of the Company’s deferred tax accounts at March 31, 2018 and December 31, 2017:

Deferred Tax Account - noncurrent:	March 31, 2018			December 31, 2017
Tax losses carryforwards	$	647,960		$	594,501
Less: Valuation allowance		(647,960	)		(594,501	)
Total deferred tax account - noncurrent	$	-		$	-

	For the Three Months Ended March 31,
	2018			2017
Statutory federal tax benefit, net of state tax effects		19	%		31	%
State income taxes		8.84	%		8.84	%
Nondeductible/nontaxable items		(2	)%		(1	)%
Change in valuation allowance		(24.84	)%		(38.84	)%
Effective income tax rate		1	%		-	%

XML 25 R14.htm IDEA: XBRL DOCUMENT

Loss per Share

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

LOSS PER SHARE

9. LOSS PER SHARE

	For the Three Months Ended March 31,
	2018			2017

Numerator:
Net loss	$	(262,040	)		(256,671	)

Denominator:
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic		213,754,639			212,056,647
Stock options		-			-
Weighted-average shares outstanding - Diluted		213,754,639			212,056,647

Loss per share
-Basic		(0.00	)		(0.00	)
-Diluted		(0.00	)		(0.00	)

Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

Operating Commitment

The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of March 31, 2018 are payable as follows:

As of March 31,	Amount
2019	$	2,463
2020		-
Total minimum payments	$	2,463

Rental expense was $2,533 and $14,330 for the three months ended March 31, 2018 and 2017, respectively.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Event

3 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENT

11. SUBSEQUENT EVENT

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Fair Value Measurements

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of March 31, 2018 and December 31, 2017.

Cash and Cash Equivalents

Concentration of Credit Risk

Receivable from Collaboration Partners

Research and Development Expenses

Stock-based Compensation

Income Taxes

For the three months ended March 31, 2018 and 2017, the Company’s income tax expense amounted to $1,850 and $830, respectively.

Loss Per Share of Common Stock

Commitments and Contingencies

Recent Accounting Pronouncements

On December 22, 2017, the SEC issued Staff Accounting Bulletin (“SAB 118”), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. In March 2018, the FASB issued ASU 2018-05, Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update), Income Taxes (Topic 740). ASU 2018-05 provides guidance regarding the recording of tax impacts where uncertainty exists, in the period of adoption of the 2017 U.S. Tax Cuts and Jobs Act (the “2017 Tax Act”).To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions we may take. The Company is continuing to gather additional information to determine the final impact.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of accrued expenses

	March 31, 2018		December 31, 2017
Accrued consulting fee	$	26,000	$	29,075
Accrued professional service fees		12,961		13,592
Accrued interest expense – related party(Note 6)		19,160		17,460
Accrued payroll		141,500		110,800
Accrued operating expenses		3,063		-
Total	$	202,684	$	170,927

XML 30 R19.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Tables)

3 Months Ended

Mar. 31, 2018

Schedule of related party transactions

Name of entity or Individual		Relationship with the Company and its subsidiaries
BioLite Inc. (the “BioLite”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst Corporation (the “BioFirst”)		Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)		Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”)		Controlling beneficiary shareholder of the Company
AsianGene Corporation (the “AsianGene”)		Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang		Chairman, interim CFO and former President

Schedule of amount due to related party

	March 31,		December 31,
	2018		2017
BioLite, Inc.	$	109,220	$	109,220
BioFirst Corporation		3,964,000		3,957,000
AsianGene Corporation		160,000		160,000
YuanGene Corporation		53,000		3,000
Eugene Jiang		100		100
Total	$	4,286,320	$	4,229,320

XML 31 R20.htm IDEA: XBRL DOCUMENT

Income Tax (Tables)

3 Months Ended

Mar. 31, 2018

Income Tax Disclosure [Abstract]

Summary of income tax (benefits)

	For the Three Months Ended March 31,
	2018						2017
	Federal		State		Total		Federal		State		Total
Current	$	-	$	1,850	$	1,850	$	-	$	830	$	830
Deferred		-		-		-		-		-		-
	$	-	$	1,850	$	1,850	$	-	$	830	$	830

Schedule of deferred tax

Deferred Tax Account - noncurrent:	March 31, 2018			December 31, 2017
Tax losses carryforwards	$	647,960		$	594,501
Less: Valuation allowance		(647,960	)		(594,501	)
Total deferred tax account - noncurrent	$	-		$	-

Schedule of statutory rate and effective rate reconciliation

	For the Three Months Ended March 31,
	2018			2017
Statutory federal tax benefit, net of state tax effects		19	%		31	%
State income taxes		8.84	%		8.84	%
Nondeductible/nontaxable items		(2	)%		(1	)%
Change in valuation allowance		(24.84	)%		(38.84	)%
Effective income tax rate		1	%		-	%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Loss per Share (Tables)

3 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Schedule of loss per share

	For the Three Months Ended March 31,
	2018			2017

Numerator:
Net loss	$	(262,040	)		(256,671	)

Denominator:
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic		213,754,639			212,056,647
Stock options		-			-
Weighted-average shares outstanding - Diluted		213,754,639			212,056,647

Loss per share
-Basic		(0.00	)		(0.00	)
-Diluted		(0.00	)		(0.00	)

XML 33 R22.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of future minimum lease payments

As of March 31,	Amount
2019	$	2,463
2020		-
Total minimum payments	$	2,463

XML 34 R23.htm IDEA: XBRL DOCUMENT

Organization and Description of Business (Details)	Feb. 08, 2016 shares
Share Exchange Agreement [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	164,387,376
Common stock issued pre-stock split	52,336,000
Share Exchange Agreement One [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	166,273,921
Common stock issued pre-stock split	52,936,583
Share Exchange Agreement Two [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	163,159,952
Common stock issued pre-stock split	51,945,225
Percentage of common shares issued and outstanding	79.70%
Percentage of issued share capital	100.00%
Share Exchange Agreement Three [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	166,273,921
Common stock issued pre-stock split	52,936,583
Common stock converted to exchange ratio	0.2536-for-1
Share Exchange Agreement Four [Member]
Organization and Description of Business (Textual)
Common stock issued post-stock split	205,519,223
Common stock issued pre-stock split	65,431,144
Percentage of common shares issued and outstanding	79.70%

XML 35 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)		3 Months Ended
	Mar. 21, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 28, 2018	Dec. 31, 2017	Dec. 31, 2016
Summary of Significant Accounting Policies (Textual)
Forward split ratio	1 to 3.141
Common stock, par value		$ 0.001		$ 1.60	$ 0.001
Common stock, authorized		360,000,000			360,000,000
Cash and cash equivalents		$ 5,675	$ 106,410		$ 93,332	$ 18,645
Income tax expense		1,850	830
Employee stock-based compensation expenses		0	0
Non-employee stock-based compensation expenses		$ 5,626	$ 3,376
Income taxes ultimate settlement, percentage		50.00%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Going Concern (Details) - USD ($)	3 Months Ended
Going Concern (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Going Concern (Textual)
Accumulated deficit	$ (16,038,638)		$ (15,776,598)
Net loss	(262,040)	$ (256,671)
Working capital deficiency	$ 1,933,329

XML 37 R26.htm IDEA: XBRL DOCUMENT

Collaborative Agreements (Details) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

May 06, 2016

Dec. 29, 2015

Sep. 25, 2017

Jul. 24, 2017

May 26, 2017

Feb. 28, 2017

Mar. 31, 2016

Mar. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Collaborative Agreements (Textual)

Outstanding balance

$ 2,550,000

Collaborative Arrangement One [Member]

Collaborative Agreements (Textual)

Percentage of payments under collaborative agreement

6.50%

Milestone payments to BioLite in cash

$ 650,000

Common stock newly issued, value

$ 5,850,000

Common stock newly issued, shares

2,925,000

Share price

$ 2.00

Licensing rights

$ 3,000,000

Accounts payable

$ 6,500,000

Research and development expense

$ 3,000,000

Collaborative Arrangement [Member]

Collaborative Agreements (Textual)

Description of payment settlement

	●	upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.

	●	upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.

	●	upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.

	●	at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.

	●	upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.

Amount received from BriVision

$ 100,000,000

$ 3,000,000

Upfront payments

$ 3,500,000

Percentage of payments under collaborative agreement

3.50%

50.00%

15.00%

Milestone payments to BioLite in cash

$ 2,600,000

Common stock newly issued, value

$ 900,000

$ 3,000,000

Common stock newly issued, shares

562,500

Share price

$ 1.60

$ 2.0

Licensing rights

$ 10,000,000

Accounts payable

$ 15,000,000

Agreement, terms

Co-Dev Agreement [Member]

Collaborative Agreements (Textual)

Amount received from BriVision

$ 3,000,000

450,000

Percentage of payments under collaborative agreement

50.00%

Company cash payments

$ 3,000,000

Outstanding balance

$ 2,550,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued consulting fee	$ 26,000	$ 29,075
Accrued professional service fees	12,961	13,592
Accrued interest expense - related party(Note 6)	19,160	17,460
Accrued payroll	141,500	110,800
Accrued operating expenses	3,063
Total	$ 202,684	$ 170,927

XML 39 R28.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Details)	3 Months Ended
Related Parties Transactions (Details)	Mar. 31, 2018
BioLite Inc. [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst Corporation [Member]
Relationship with the Company and its subsidiaries, description	Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Controlling beneficiary shareholder of the Company
AsianGene Corporation [Member]
Relationship with the Company and its subsidiaries, description	Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang [Member]
Relationship with the Company and its subsidiaries, description	Chairman, interim CFO and former President

XML 40 R29.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Details 1) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Due to related parties	$ 4,286,320	$ 4,229,320
BioLite Inc. [Member]
Due to related parties	109,220	109,220
BioFirst Corporation [Member]
Due to related parties	3,964,000	3,957,000
AsianGene Corporation [Member]
Due to related parties	160,000	160,000
YuanGene Corporation [Member]
Due to related parties	53,000	3,000
Eugene Jiang [Member]
Due to related parties	$ 100	$ 100

XML 41 R30.htm IDEA: XBRL DOCUMENT

Related Parties Transactions (Details Textual) - USD ($)	1 Months Ended		3 Months Ended			12 Months Ended
	Jan. 18, 2018	Jan. 26, 2017	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Sep. 25, 2017	May 26, 2017
Related Parties Transactions (Textual)
Amount received from BriVision			$ 4,286,320	$ 4,229,320		$ 4,229,320
Outstanding loan			950,000	950,000
Accrued interest			17,960	17,460
Interest expenses			33,645		$ 19,000
Aggregate working capital			$ 14,000	7,000
Interest rate percentage			0.00%
Stock based compensation expenses			$ 5,626		3,376
Additional paid-in capital			13,891,382	13,805,936		13,805,936
Monthly base rent			5,000
Rent expenses			$ 0		15,000
Related party transactions, description			Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by AsianGene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. As of March 31, 2018 and December 31, 2017, Everfront only paid $160,000 to AsianGene. AsianGene also agreed to loan the proceeds to the Company for working capital purpose. On January 16, 2018, AsianGene and the Company entered into a loan agreement. Pursuant to the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 15, 2019.
Chairman [Member]
Related Parties Transactions (Textual)
Aggregate working capital			$ 100			$ 100
Interest rate percentage			0.00%			0.00%
Loan Agreement [Member]
Related Parties Transactions (Textual)
Total commitment		$ 950,000
Loan maturity date		Feb. 01, 2018
Loan agreement, description		The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.
Co-Dev Agreement [Member]
Related Parties Transactions (Textual)
Amount received from BriVision			$ 450,000	450,000		$ 450,000			$ 3,000,000
Common stock new issues			2,550,000	2,550,000			$ 3,000,000
Additional paid-in capital							$ 3,000,000
Asiangene Corporation [Member]
Related Parties Transactions (Textual)
Amount received from BriVision			160,000	160,000		160,000
Outstanding loan			160,000	160,000
Interest expenses			3,945		0
BioLite [Member]
Related Parties Transactions (Textual)
Aggregate working capital			$ 109,220	$ 109,220
Interest rate percentage			0.00%	0.00%
BioFirst Collaborative Agreement [Member]
Related Parties Transactions (Textual)
Due to BioFirst								$ 3,000,000
YuanGene Corporation [Member]
Related Parties Transactions (Textual)
Amount received from BriVision			$ 53,000	$ 3,000		3,000
Outstanding loan			50,000			0
Accrued interest			1,200			0
Interest expenses			1,200		$ 0
Aggregate working capital	$ 50,000		$ 3,000			$ 3,000
Interest rate percentage			0.00%			0.00%
Related party transactions, description	Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender. The loan will be matured on January 17, 2017.

XML 42 R31.htm IDEA: XBRL DOCUMENT

Equity (Details) - USD ($)					1 Months Ended							3 Months Ended	12 Months Ended
Equity (Details) - USD ($)	May 06, 2016	Mar. 21, 2016	Feb. 08, 2016	Dec. 29, 2015	Jul. 24, 2017	May 26, 2017	Feb. 28, 2017	Oct. 02, 2016	Aug. 26, 2016	Mar. 31, 2016	Feb. 17, 2016	Mar. 31, 2018	Dec. 31, 2017	Mar. 28, 2018	Oct. 30, 2015
Equity (Textual)
Common stock, authorized												360,000,000	360,000,000
Common stock, par value												$ 0.001	$ 0.001	$ 1.60
Description of forward split		1 to 3.141
Subscription receivable															$ 350,000
Due to related parties												$ 4,286,320	$ 4,229,320
Common stock, shares issued												213,926,475	213,746,647	50,000
Common stock, shares issued total														80,000
Kimho Consultants Co., Ltd [Member]
Equity (Textual)
Common stock, par value														$ 1.60
Common stock, shares issued														75,000
Common stock, shares issued total														120,000
BioLite, Inc. [Member]
Equity (Textual)
Common stock, par value									$ 0.001
Issuance of common shares									$ 1,468,750
Purchase price per share									$ 1.60
Net proceeds from offering									$ 2,350,000
Equity Incentive Plan [Member]
Equity (Textual)
Common stock issued pre-stock split											50,000
Common stock issued post-stock split											157,050
Collaborative Arrangement [Member]
Equity (Textual)
Issuance of common shares	$ 900,000				$ 3,000,000
Issuance of common shares, shares	562,500
Share price	$ 1.60						$ 2.0
Due to related parties					$ 3,000,000							$ 100,000,000
Total payment upon first IND submission												$ 15,000,000
Percentage of payments under collaborative agreement				3.50%	50.00%							15.00%
Consulting agreement, description								The Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000.
Share Exchange Agreement Four [Member]
Equity (Textual)
Common stock issued pre-stock split			65,431,144
Common stock issued post-stock split			205,519,223
Percentage of common shares issued and outstanding			79.70%
Share Exchange Agreement [Member]
Equity (Textual)
Common stock issued pre-stock split			52,336,000
Common stock issued post-stock split			164,387,376
Share Exchange Agreement One [Member]
Equity (Textual)
Common stock issued pre-stock split			52,936,583
Common stock issued post-stock split			166,273,921
Share Exchange Agreement Two [Member]
Equity (Textual)
Common stock issued pre-stock split			51,945,225
Common stock issued post-stock split			163,159,952
Percentage of common shares issued and outstanding			79.70%
Percentage of issued share capital			100.00%
Share Exchange Agreement Three [Member]
Equity (Textual)
Common stock issued pre-stock split			52,936,583
Common stock issued post-stock split			166,273,921
Exchange ratio			0.2536-for-1
Co-Dev Agreement [Member]
Equity (Textual)
Company cash payments						$ 3,000,000							$ 3,000,000
Due to related parties						$ 3,000,000
Percentage of payments under collaborative agreement						50.00%
Collaborative Arrangement One [Member]
Equity (Textual)
Issuance of common shares							$ 5,850,000
Issuance of common shares, shares							2,925,000
Share price							$ 2.00
Due to related parties									$ 100,000,000
Total payment upon first IND submission										$ 6,500,000
Percentage of payments under collaborative agreement										6.50%
Remitted amount							$ 650,000
Consulting Agreement [Member]
Equity (Textual)
Common stock, par value														$ 1.60
Common stock, shares issued														4,828
Common stock, shares issued total														7,725
Euro-Asia Investment & Finance Corp Ltd. [Member]
Equity (Textual)
Common stock, par value														$ 1.60
Common stock, shares issued														50,000
Common stock, shares issued total														80,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

Income Tax (Details) - USD ($)	3 Months Ended
Income Tax (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Federal
Current
Deferred
Federal Total
State
Current	1,850	830
Deferred
State total	1,850	830
Current total	1,850	830
Deferred total
Total	$ 1,850	$ 830

XML 44 R33.htm IDEA: XBRL DOCUMENT

Income Tax (Details 1) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Deferred Tax Account - noncurrent:
Tax losses carryforwards	$ 647,960	$ 594,501
Less: Valuation allowance	(647,960)	(594,501)
Total deferred tax account - noncurrent

XML 45 R34.htm IDEA: XBRL DOCUMENT

Income Tax (Details 2)	3 Months Ended
Income Tax (Details 2)	Mar. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory federal tax benefit, net of state tax effects	19.00%	31.00%
State income taxes	8.84%	8.84%
Nondeductible/nontaxable items	(2.00%)	(1.00%)
Change in valuation allowance	(24.84%)	(38.84%)
Effective income tax rate	1.00%	0.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Income Tax (Details Textual)	1 Months Ended
Income Tax (Details Textual)	Dec. 22, 2017
Income Tax (Textual)
Corporate tax rate, description	H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 35% to 21% effective January 1, 2018. The 21% Federal Tax Rate will apply to earnings reported for the full 2018 fiscal year. In addition, the Company must re-measure its net deferred tax assets and liabilities using the Federal Tax Rate that will apply when these amounts are expected to reverse. As of March 31, 2018 and December 31, 2017, the Company can determine a reasonable estimate for certain effects of tax reform and is recording that estimate as a provisional amount. The provisional remeasurement of the deferred tax assets and allowance valuation of deferred tax assets at March 31, 2018 and December 31, 2017 resulted in a net effect of $0 discrete tax expenses (benefit) which lowered the effective tax rate by 13% for the three months ended March 31, 2018 and for the year ended December 31, 2017.

XML 47 R36.htm IDEA: XBRL DOCUMENT

Loss per Share (Details) - USD ($)	3 Months Ended
Loss per Share (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Numerator:
Net loss	$ (262,040)	$ (256,671)
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic	213,754,639	212,056,647
Stock options
Weighted-average shares outstanding - Diluted	213,754,639	212,056,647
Loss per share
-Basic	$ (0.00)	$ (0.00)
-Diluted	$ (0.00)	$ (0.00)

XML 48 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	Mar. 31, 2018 USD ($)
Operating Leases, Future Minimum Payments [Abstract]
2019	$ 2,463
2020
Total minimum payments	$ 2,463

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Commitments and Contingencies (Textual)
Rent expense	$ 2,533	$ 14,330

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *Z&KTP?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ KH:O3&;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " "NAJ],[%V96>\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*$Z6,DSJ2\M.&PQ6V-C-V&IK&L?&UDCZ]DNR M-F5L#["CI=^?/H$:'83V$5^B#QC)8KH;7-LEH<.:'8F" $CZB$ZE?$QT8W/O MHU,T/N,!@M(G=4 HBV(%#DD910HF8!86(I.-T4)'5.3C!6_T@@^?L9UA1@.V MZ+"C!#SGP.0T,9R'MH$;8((11I>^"V@6XES]$SMW@%V20[)+JN_[O*_FW+@# MA_?GI]=YW,K49?BOOJ8 M7'_XW82=-W9O_['Q55 V\.LNY!=02P,$% @ KH:O3)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " "NAJ],#'1TT68" 6" & 'AL+W=O\;?1$FI#-Z;NA6;L)2R>P9 G$K:$/'$.MJJ MDPOC#9%JR:] =)R2LR$U-4!1E(*&5&U8Y&;OP(NZ%".C+WIQ=?S)HRT1[2F)ZE-$#7>FSH\8R>6 EP$:E?(/$*) X] MLP0&1&(0[9!AF&$,%]*0>F521V9ER;B(M5\@\PID#AW:5\4#6;@K*Z_$RN5; MEV7G@2RD:>V56+O\V)+P0!*_!(S\-16Y%E*[JCR8;$%EH7*A:\'^Y"-F?K50 M-$,]ZG@+> N1J[.V=09,.J_R:$'%7\40.RH(VBH>#%I0\1<[=&L98>LY&C$/ M.8-XC=(XLZ\!F+VR#>57TY!$<&*WUG3#V>[4]+;(O-+_X$/'_$[XM6I%<&12 MO?7F1;XP)JGR*'I2OI2J24^+FEZDGF9JSH=.-2PDZ\8N#*:_ L5?4$L#!!0 M ( *Z&KTS3,TT]W@( "D+ 8 >&PO=V]R:W-H965T&ULC99M;YLP%(7_"N)[BU\PQE42:E3+12U76[3(^&G-Z2))V>U25;._U2=7VE[UN M*FELLSDD[:E15;/ZN5:FO MRQC'KQW?B\/1=!W):G&2!_5#F9^GQ\:VDG&475&INBUT'35JOXP_X(<-YIW! M*7X5ZMI.[J.NE">MG[O&E]TR1AV1*M76=$-(>[FHC2K+;B3+\6<8-![G[(S3 M^]?1/[GB;3%/LE4;7?XN=N:XC/,XVJF]/)?FN[Y^5D-!+(Z&ZK^JBRJMO".Q M2VDE8QIE71R@2E%(" MHZ0@2AJBY!Y*+V&360ACR'X\FO=U-SP,Y&$AC_!X�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
XML 51 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 81 160 1 false 24 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://metuboutique.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://metuboutique.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://metuboutique.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://metuboutique.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://metuboutique.com/role/ConsolidatedStatementsOfCashFlow Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Description of Business Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://metuboutique.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Collaborative Agreements Sheet http://metuboutique.com/role/CollaborativeAgreement Collaborative Agreements Notes 9 false false R10.htm 00000010 - Disclosure - Accrued Expenses Sheet http://metuboutique.com/role/AccruedExpenses Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Related Parties Transactions Sheet http://metuboutique.com/role/RelatedPartiesTransactions Related Parties Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Equity Sheet http://metuboutique.com/role/Equity Equity Notes 12 false false R13.htm 00000013 - Disclosure - Income Tax Sheet http://metuboutique.com/role/IncomeTax Income Tax Notes 13 false false R14.htm 00000014 - Disclosure - Loss per Share Sheet http://metuboutique.com/role/EarningsPerShare Loss per Share Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://metuboutique.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Event Sheet http://metuboutique.com/role/SubsequentEvent Subsequent Event Notes 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://metuboutique.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Accrued Expenses (Tables) Sheet http://metuboutique.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://metuboutique.com/role/AccruedExpenses 18 false false R19.htm 00000019 - Disclosure - Related Parties Transactions (Tables) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsTables Related Parties Transactions (Tables) Tables http://metuboutique.com/role/RelatedPartiesTransactions 19 false false R20.htm 00000020 - Disclosure - Income Tax (Tables) Sheet http://metuboutique.com/role/IncomeTaxTables Income Tax (Tables) Tables http://metuboutique.com/role/IncomeTax 20 false false R21.htm 00000021 - Disclosure - Loss per Share (Tables) Sheet http://metuboutique.com/role/EarningsPerShareTables Loss per Share (Tables) Tables http://metuboutique.com/role/EarningsPerShare 21 false false R22.htm 00000022 - Disclosure - Commitments and Contingencies (Tables) Sheet http://metuboutique.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://metuboutique.com/role/CommitmentsAndContingencies 22 false false R23.htm 00000023 - Disclosure - Organization and Description of Business (Details) Sheet http://metuboutique.com/role/OrganizationAndDescriptionOfBusinessDetails Organization and Description of Business (Details) Details http://metuboutique.com/role/OrganizationAndDescriptionOfBusiness 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://metuboutique.com/role/SummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 00000025 - Disclosure - Going Concern (Details) Sheet http://metuboutique.com/role/GoingConcernDetails Going Concern (Details) Details http://metuboutique.com/role/GoingConcern 25 false false R26.htm 00000026 - Disclosure - Collaborative Agreements (Details) Sheet http://metuboutique.com/role/CollaborativeAgreementDetails Collaborative Agreements (Details) Details http://metuboutique.com/role/CollaborativeAgreement 26 false false R27.htm 00000027 - Disclosure - Accrued Expenses (Details) Sheet http://metuboutique.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://metuboutique.com/role/AccruedExpensesTables 27 false false R28.htm 00000028 - Disclosure - Related Parties Transactions (Details) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails Related Parties Transactions (Details) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 28 false false R29.htm 00000029 - Disclosure - Related Parties Transactions (Details 1) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetails1 Related Parties Transactions (Details 1) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 29 false false R30.htm 00000030 - Disclosure - Related Parties Transactions (Details Textual) Sheet http://metuboutique.com/role/RelatedPartiesTransactionsDetailsTextual Related Parties Transactions (Details Textual) Details http://metuboutique.com/role/RelatedPartiesTransactionsTables 30 false false R31.htm 00000031 - Disclosure - Equity (Details) Sheet http://metuboutique.com/role/EquityDetails Equity (Details) Details http://metuboutique.com/role/Equity 31 false false R32.htm 00000032 - Disclosure - Income Tax (Details) Sheet http://metuboutique.com/role/IncomeTaxDetails Income Tax (Details) Details http://metuboutique.com/role/IncomeTaxTables 32 false false R33.htm 00000033 - Disclosure - Income Tax (Details 1) Sheet http://metuboutique.com/role/IncomeTaxDetails1 Income Tax (Details 1) Details http://metuboutique.com/role/IncomeTaxTables 33 false false R34.htm 00000034 - Disclosure - Income Tax (Details 2) Sheet http://metuboutique.com/role/IncomeTaxDetails2 Income Tax (Details 2) Details http://metuboutique.com/role/IncomeTaxTables 34 false false R35.htm 00000035 - Disclosure - Income Tax (Details Textual) Sheet http://metuboutique.com/role/IncomeTaxtextual Income Tax (Details Textual) Details http://metuboutique.com/role/IncomeTaxTables 35 false false R36.htm 00000036 - Disclosure - Loss per Share (Details) Sheet http://metuboutique.com/role/EarningsPerShareDetails Loss per Share (Details) Details http://metuboutique.com/role/EarningsPerShareTables 36 false false R37.htm 00000037 - Disclosure - Commitments and Contingencies (Details) Sheet http://metuboutique.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://metuboutique.com/role/CommitmentsandContingenciesTables 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://metuboutique.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://metuboutique.com/role/CommitmentsandContingenciesTables 38 false false All Reports Book All Reports abvc-20180331.xml abvc-20180331.xsd abvc-20180331_cal.xml abvc-20180331_def.xml abvc-20180331_lab.xml abvc-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 56 0001213900-18-006355-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-18-006355-xbrl.zip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�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end